About Leukocyte elastase inhibitor
Leukocyte elastase inhibitor (SERPINB1) is a protein
from Homo sapiens identified by UniProt accession
P30740, 379 residues long.
MolForge cross-references it against 0 known binders and
363 disease associations.
Target properties
| Protein name | Leukocyte elastase inhibitor |
|---|
| UniProt accession | P30740 |
|---|
| Gene | SERPINB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 379 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (363)
Diseases linked to this target (Open Targets).
- beta-amyloid 1-42 measurement · score 0.29
- type 2 diabetes mellitus · score 0.08
- gestational diabetes · score 0.07
- acute myocardial infarction · score 0.07
- heel bone mineral density · score 0.07
- isolated agammaglobulinemia · score 0.07
- infection · score 0.06
- infect · score 0.06
- respiratory distress syndrome in premature infants · score 0.06
- common variable immunodeficiency · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30740-F1 | alphafold | PREDICTED | 92.47 | — |
Amino-acid sequence (379 residues)
MEQLSSANTR FALDLFLALS ENNPAGNIFI SPFSISSAMA MVFLGTRGNT AAQLSKTFHF NTVEEVHSRF QSLNADINKR GASYILKLAN RLYGEKTYNF LPEFLVSTQK TYGADLASVD FQHASEDARK TINQWVKGQT EGKIPELLAS GMVDNMTKLV LVNAIYFKGN WKDKFMKEAT TNAPFRLNKK DRKTVKMMYQ KKKFAYGYIE DLKCRVLELP YQGEELSMVI LLPDDIEDES TGLKKIEEQL TLEKLHEWTK PENLDFIEVN VSLPRFKLEE SYTLNSDLAR LGVQDLFNSS KADLSGMSGA RDIFISKIVH KSFVEVNEEG TEAAAATAGI ATFCMLMPEE NFTADHPFLF FIRHNSSGSI LFLGRFSSP
Explore Leukocyte elastase inhibitor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets